TITLE

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics

AUTHOR(S)

Benmessaoud, Dalila; Hamdani, Nora; Boni, Claudette; Ramoz, Nicolas; Hamon, Michel; Kacha, Farid; Gorwood, Philip

PUB. DATE

January 2008

SOURCE

BMC Psychiatry;2008, Vol. 8, Special section p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: The -1438A/G polymorphism of the 5-HT2A gene has been found to be associated with clinical response to clozapine and other second generation antipsychotics. Testing the impact of this marker on response to first generation antipsychotics (which have a lower affinity for the 5-HT2A receptor) provides the opportunity to help disentangling the two different roles that this polymorphism might have. A psychopharmacogenetic role should be detected only for antipsychotics with high affinity to the 5-HT2A receptor (therefore to second generation antipsychotics). An alternative role would imply tagging a subgroup of patients responsive to any antipsychotic, whatever their affinity, meaning that the association is more depending on non pharmacological charaterictics, such as clinical specificities. Methods: A family-based sample of 100 Algerian patients with schizophrenia (according to DSM-IV criteria) and their 200 biological parents was recruited, in order to avoid stratification biases. Patients were all treated, or have been treated, by conventional antipsychotics (mainly haloperidol) for at least four weeks, at appropriate dosage. May and Dencker scale was used to distinguish responders and non responders. Results: No allele of the -1438A/G polymorphism of the 5-HT2A gene was transmitted in excess (50 transmitted for 38 untransmitted) in the whole sample of patients with schizophrenia (p = .90). In contrast, a significant excess of transmission of the G allele was observed (p = .02) in the subgroup of patients with good treatment response (17 transmitted for 6 untransmitted). Conclusion: Using a TDT approach, we showed that the G allele of the -1438A/G polymorphism of the gene coding for the 5-HT2A receptor was associated to schizophrenia with good response to conventional antipsychotics, although this conclusion is based on 88 informative patients only. Because previous data showed the same result with atypical antipsychotics, it can be concluded that the G allele tags a subgroup of schizophrenic patients with greater chance of improvement with antipsychotics of either type.

ACCESSION #

35702796

 

Related Articles

• Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Nikolac Perkovic, Matea; Nedic Erjavec, Gordana; Zivkovic, Maja; Sagud, Marina; Uzun, Suzana; Mihaljevic-Peles, Alma; Kozumplik, Oliver; Muck-Seler, Dorotea; Pivac, Nela // Psychopharmacology;Sep2014, Vol. 231 Issue 18, p3757 

  Rationale: Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several neurotransmitter systems including the dopaminergic system. There are mixed reports about the association between the BDNF Val66Met...

• Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Liou, Y-J; Bai, Y M; Lin, E; Chen, J-Y; Chen, T-T; Hong, C-J; Tsai, S-J // Pharmacogenomics Journal;Feb2012, Vol. 12 Issue 1, p54 

  The use of atypical antipsychotics (AAPs) is associated with increasing the risk of the metabolic syndrome (MetS), which is an important risk factor for cardiovascular disease and diabetes. Two insulin-induced gene (INSIG) isoforms, designated INSIG-1 and INSIG-2 encode two proteins that mediate...

• Polymorphism of the adrenergic receptor alpha 2a −1291C>G genetic variation and clozapine-induced weight gain. Wang, Y.-C.; Bai, Y.-M.; Chen, J.-Y.; Lin, C.-C.; Lai, I.-C.; Liou, Y.-J. // Journal of Neural Transmission;Nov2005, Vol. 112 Issue 11, p1463 

  Weight gain, leading to further morbidity and poor treatment compliance, is a common consequence of treatment with clozapine. The substantial interindividual and interracial differences in drug-induced weight gain suggest that genetic factors may be important. Several studies showed that...

• CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia. Balibey, Hakan; Basoglu, Cengiz; Lundgren, Stefan; Babaoglu, Melih O.; Yasar, Umit; Herken, Hasan; Rane, Anders; Bozkurt, Atilla; Cetin, Mesut // Klinik Psikofarmakoloji Bulteni;Jun2011, Vol. 21 Issue 2, p93 

  Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or occurrence of side effects of antipsychotic drugs. Aim: We studied the association of response to clozapine treatment in schizophrenic patients in relation to polymorphisms in the CYP1A2 gene....

• Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Cai, Jun; Zhang, Wen; Yi, Zhenghui; Lu, Weihong; Wu, Zhiguo; Chen, Jun; Yu, Shunying; Fang, Yiru; Zhang, Chen // Psychopharmacology;Nov2013, Vol. 230 Issue 1, p49 

  Rationale: Clinical observations indicate that atypical antipsychotics, especially clozapine, induce obsessive-compulsive (OC) symptoms in schizophrenia patients. Recent data from neuroimaging and clinical trials suggest a role for altered glutamate neurotransmission in the etiology of OC...

• Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Hwang, Rudi; Shinkai, Takahiro; De Luca, Vincenzo; Müller, Daniel J.; Xingqun Ni; Macciardi, Fabio; Potkin, Steven; Lieberman, Jeffrey A.; Meltzer, Herbert Y.; Kennedy, James L. // Psychopharmacology;Aug2005, Vol. 181 Issue 1, p179 

  Dopamine D2 receptor blockade is the major basis for the antipsychotic action of typical antipsychotic drugs (AP) and a necessary but not sufficient basis for the antipsychotic action of atypical APs such as clozapine and other multireceptor antagonists which rely, in part, upon 5-HT2A...

• Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Arranz, M.J.; Munro, J.; Owen, M.J.; Spurlock, G.; Sham, P.C.; Zhao, J.; Kirov, G.; Collier, D.A.; Kerwin, R.W. // Molecular Psychiatry;1998, Vol. 3 Issue 1, p61 

  Clozapine is a potent atypical antipsychotic which binds to a variety of neurotransmitter receptors including serotonin (5-HT) receptors. However, the precise neurochemical site of clozapine's therapeutic action is unknown. We hypothesize that genetic variation in the neurotransmitter receptors...

• Clinical Chemistry and Metabolic Medicine, 7th edn. Day, Andrew // Annals of Clinical Biochemistry;Mar2007, Vol. 44 Issue 2, p199 

  The article reviews the book " Clinical Chemistry and Metabolic Medicine," 7th edn., edited by M. Crook.

• A Bioequivalence Study of Brand and Generic Clozapine in Patients with Schizophrenia: Pharmacokinetic and Tolerability Findings. Sramek, J.J.; Anand, R.; Hartman, R.D.; Schran, H.F.; Hourani, J.; Barto, S.; Wardle, T.S.; Shiovitz, T.M.; Cutler, N.R. // Clinical Drug Investigation;1999, Vol. 17 Issue 1, p51 

  Objective: This inpatient, randomised, three-way crossover study evaluated the steady-state pharmacokinetics and tolerability of generic clozapine (Creighton) versus Clozaril (Novartis brand of clozapine) in patients with schizophrenia. Setting: Patients were hospitalised throughout the study....

Read the Article